Innovative Polygenic Risk Scores From Mass General Brigham Surpass Traditional Body Mass Index for Predicting Metabolic Disease Outcomes

Mass General Brigham researchers develop polygenic risk scores using 8.5 million profiles to predict diabetes and obesity outcomes across diverse populations.

By: AXL Media

Published: Mar 17, 2026, 6:09 AM EDT

Source: Information for this report was sourced from Mass General Brigham

Revolutionizing the Prediction of Metabolic Health

The traditional reliance on Body Mass Index to assess metabolic risk is being challenged by a sophisticated new genomic tool developed at Mass General Brigham. By integrating genetic data from some of the world’s most extensive biobanks, investigators have constructed polygenic risk scores capable of estimating a person’s likelihood of developing complex conditions like Type 2 diabetes and obesity. According to the study published in Cell Metabolism, these scores do not merely predict a diagnosis, they provide a window into a patient’s long-term health trajectory and potential for downstream morbidity.

A Multi-Trait Approach to Genetic Susceptibility

Unlike previous models that focused on isolated variables, the new metabolic PRS examines 20 distinct traits related to internal function, including glucose control, insulin levels, and fat distribution. The research team utilized genome-wide association studies encompassing over 8.5 million global participants to ensure the scores reflect a holistic view of metabolic health. Co-first author Min Seo Kim, MD, MSc, stated that the intention was to capture risk across the entire life course by integrating these various aspects of function, rather than relying on a single snapshot of a patient's current weight or height.

Predicting Clinical Interventions and Morbidity

The practical application of these scores was demonstrated through their ability to identify high-risk individuals before they developed chronic conditions. During a median follow-up period of 5.5 years, initially healthy individuals with high risk scores were found to be twice as likely to eventually require bariatric surgery or GLP-1 agonist medications compared to those with average scores. Furthermore, the study revealed that these high-risk individuals faced significantly higher probabilities of suffering from severe clinical outcomes, such as cardiovascular disease and stroke, marking the PRS as a vital tool for early preventative medicine.